
Ocugen’s Stargardt Disease Therapy OCU410ST Receives FDA Alignment for Pivotal Clinical Trials
Ocugen’s OCU410ST Receives FDA Green Light for Phase 2/3 Pivotal Trial On February 27, 2025, Ocugen, Inc., a trailblazing biotechnology company specializing in gene therapies for blindness diseases (NASDAQ: OCGN), made a significant announcement. The company revealed that they have reached alignment with the U.S. Food and Drug Administration (FDA) to progress with a Phase…